|
|
SVT的患者
(= 90) |
|
| 年龄(年),中等(差) |
50 (39 - 62) |
| 男性,(%) |
47/90 (52.2%) |
| 个人历史的静脉血栓栓塞,(%) |
7/90 (7.8%) |
| 静脉血栓栓塞的家族史,(%) |
8/90 (8.9%) |
| 无症状的偶然发现SVT,(%) |
11/90 (12.2%) |
| 风险因素 |
|
| 无缘无故的SVT,(%) |
33/90 (36.7%) |
| 肝硬化,(%) |
14/90 (15.6%) |
| 固体癌症,(%) |
6/90 (6.7%) |
| 骨髓增殖性肿瘤,(%) |
7/90 (7.8%) |
| 最近的腹部手术,(%) |
10/90 (11.1%) |
| 激素治疗,女(%) |
11/43 (25.6%) |
| 炎症性肠病,(%) |
5/90 (5.6%) |
| 其他腹腔炎症或感染,(%) |
7/90 (7.8%) |
| 涉及静脉 |
|
| 多个静脉血栓形成,(%) |
33/90 (36.7% |
| 孤立的门静脉血栓形成,(%) |
35/90 (38.9%) |
| 孤立的肠系膜静脉血栓形成,(%) |
16/90 (17.8%) |
| 孤立的suprahepatic静脉血栓形成,(%) |
1/90 (1.1%) |
| 孤立的脾静脉血栓形成,(%) |
5/90 (5.6%) |
| 基因突变 |
|
| JAK2 V617F突变,测试(%) |
3/42 (7.1%) |
| 凝血酶原G20210A突变,测试(%) |
4/55 (7.3%) |
| 因子V莱顿突变,测试(%) |
5/58 (8.6%) |
| 以前的抗凝治疗 |
|
| VKA治疗持续时间(几个月),中等(差) |
12.4 (7.1 - -23.8) |
| 不到3个月,(%) |
7/90 (7.8%) |
| 3 - 6个月,(%) |
10/90 (11.1%) |
| 6 - 12个月,(%) |
22/90 (24.4%) |
| 1年以上,(%) |
51/90 (56.7%) |
| 时间在治疗范围内(%),中等(差) |
62 (56 - 75.5) |
|
|
